Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1I | Q9P0X4 | 11/20 | 0.50 |
| ▸ | CACNA1H | O95180 | 6/20 | 0.50 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.44 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16478284 | 1.00 | CACNA1I (0.50) | CACNA1ICACNA1HCACNA1GKCNH2DPP4 | |
| SCHEMBL16478341 | 0.94 | CACNA1I (0.47) | CACNA1ICACNA1HCACNA1GKCNH2DPP4 | |
| SCHEMBL8371289 | 0.89 | CACNA1I (0.62) | CACNA1ICACNA1HCACNA1GKCNH2 | |
| SCHEMBL8374203 | 0.89 | CACNA1I (0.62) | CACNA1ICACNA1HCACNA1GKCNH2 | |
| SCHEMBL16478275 | 0.88 | CACNA1H (0.48) | CACNA1ICACNA1HCACNA1GKCNH2DPP4 | |
| SCHEMBL8371157 | 0.88 | CACNA1H (0.48) | CACNA1ICACNA1HCACNA1GKCNH2DPP4 | |
| SCHEMBL4273261 | 0.86 | CACNA1I (0.52) | CACNA1ICACNA1HCACNA1GKCNH2LMNA | |
| SCHEMBL4270504 | 0.86 | CACNA1I (0.52) | CACNA1ICACNA1HCACNA1GKCNH2LMNA | |
| SCHEMBL4270508 | 0.86 | CACNA1I (0.52) | CACNA1ICACNA1HCACNA1GKCNH2LMNA | |
| SCHEMBL8371812 | 0.86 | DPP4 (0.56) | CACNA1ICACNA1HCACNA1GKCNH2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298883-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MARK G. DEGIACOMO, CHAPTER 7 TRUSTEE OF EPIRUS BIOPHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298883-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | CACNA1I 4/4885CACNA1H 2/4885CACNA1G 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.